A diagnosis of inflammatory bowel disease (IBD) can be life-changing for children and their families, who must learn new ways of looking at food and cope with a barrage of medical appointments and treatments. No two cases of this lifelong condition are alike. The best hope for young patients to heal and live their fullest lives is to receive personalized treatment.

No More Trial and Error

Through conducting innovative research and caring for patients who come from across the country, Stanford doctors have made progress in understanding IBD. However, more research is needed to determine its root causes. Currently, there is no cure for the disease, and treatment can be complex. Often children must endure the emotional and physical toll of trying a variety of medications before finding one that works. It might take months or even years to get relief! Taking the guesswork out of prescribing the right therapies is the next frontier.

Stanford is primed to take the lead. In March 2022, we launched the West Coast’s first Center for Pediatric IBD and Celiac Disease. Michael Rosen, MD, MSCI, and a team of experts will collaborate with the entire Stanford research community—including leaders in immunology, the microbiome, genetics, and biomedical engineering—to understand the biological underpinnings of IBD. Their breakthroughs will help predict how each child will respond to certain medications, ultimately finding the best treatment, faster.

With your support, children with IBD can live their fullest lives.
Opportunity for Impact

At Stanford, we have built a strong foundation for research and care for children with IBD in record time. We are poised to make game-changing discoveries, and philanthropy will propel us forward. Help us to:

- **Advance leading-edge research** on organoids and mini guts. Using tiny 3D models of human tissue, we aim to develop new therapies and test their effectiveness before a child receives a single dose.

- **Investigate why some IBD patients respond to changes in diet**, while others don’t. Research by top Stanford scientists in related fields like the gut microbiome and nutrition could eventually lead to customized treatment approaches for every child.

- **Provide seed funding** for early-stage investigations and clinical trials. First up would be researching health inequities and their impact on the screening, diagnosis, and quality of care for children with IBD.

- **Establish an endowed surgical directorship** to recruit and retain a top surgeon with expertise in advanced IBD surgeries who will not only improve traditional surgeries but also suggest new approaches.

- **Bring state-of-the-art technology** to the bedside, such as bowel ultrasounds—a valuable non-invasive tool to assess activity and track healing in IBD patients.

Please contact: Michael Tomura
Associate Director, Major Gifts
Lucile Packard Foundation for Children’s Health
(650) 721-9347 / Michael.Tomura@lpfch.org

MEET OUR NEW CENTER’S LEADER

Michael Rosen, MD, MSCI
Stanford University Endowed Professor for Pediatric IBD and Celiac Disease

**No stranger to IBD**, Dr. Michael Rosen experienced his own personal challenges with ulcerative colitis during medical school. For 20 years, he has focused on investigating the root causes of IBD and developing better treatments that will benefit others with the condition.

**Being at Stanford**, Dr. Rosen appreciates having access to some of the brightest minds and promising innovations. These key ingredients will help him transform ideas into life-changing new treatments. Dr. Rosen explains, “We aim to build the nation’s destination center for innovation in pediatric IBD and celiac disease care, as well as a major research hub for these conditions.”

**Dr. Rosen is a national leader**, serving as co-chair of the Cohort for Pediatric Translational and Clinical Research (CAPTURE IBD), which tracks children over the course of their disease. The largest study of its kind, CAPTURE IBD will unlock unprecedented clinical and scientific information to better understand this complex disease and develop new treatments.